Zynex (ZYXI) to Release Earnings on Wednesday

Zynex (NASDAQ:ZYXI) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Zynex to post earnings of $0.09 per share and revenue of $53.65 million for the quarter.

Zynex Stock Down 3.0 %

NASDAQ:ZYXI opened at $7.19 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a market cap of $229.00 million, a PE ratio of 47.93 and a beta of 0.54. Zynex has a 52-week low of $7.12 and a 52-week high of $13.77. The stock has a 50-day simple moving average of $7.93 and a 200 day simple moving average of $8.04.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Zynex in a report on Friday, December 6th.

Insider Buying and Selling at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the transaction, the chief financial officer now directly owns 19,738 shares in the company, valued at $151,587.84. This trade represents a 33.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 30,000 shares of company stock worth $236,400 over the last ninety days. 52.13% of the stock is currently owned by corporate insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.